NewMediaWire
- Home
- GOVX
GOVX
GeoVax Labs Inc.
as of 12-12-2025 3:41pm EST
$0.37
$0.01
-3.53%
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Chart Type:
Time Range:
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | SMYRNA |
| Market Cap: | 12.2M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 538.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $2.75 | Next Earning Date: | 11-13-2025 |
| Revenue: | $3,353,560 | Revenue Growth: | 8.52% |
| Revenue Growth (this year): | -38.73% | Revenue Growth (next year): | N/A |
AI-Powered GOVX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.47%
76.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest GeoVax Labs Inc. News
GOVX Breaking Stock News: Dive into GOVX Ticker-Specific Updates for Smart Investing
NewMediaWire
GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board
📈
AI Sentiment
Highly Positive
8/10
NewMediaWire
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
📈
AI Sentiment
Highly Positive
8/10
NewMediaWire
GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer
📈
AI Sentiment
Highly Positive
8/10
Compare GOVX vs Leading Stocks
See how GOVX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GOVX GeoVax Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.